Instrument Inactif

Communiqués Kazia Therapeutics Australian S.E.

Actions

KZA

AU000000KZA9

Recherche biotechnologique et médicale

Communiqués

28/08	Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering	AQ
27/08	Kazia Therapeutics Limited Announces Proposed Public Offering	PR
27/08	Kazia Therapeutics Limited Announces Proposed Public Offering	AQ
27/08	Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer	PR
27/08	Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer	AQ
28/07	Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer	AQ
02/06	Kazia Therapeutics Appoints James Levine as Chief Financial Officer	PR
26/05	Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer	PR
28/04	Kazia Therapeutics : Corporate Overview April 2026	PU
28/04	Kazia Therapeutics : Investor Fact Sheet April 2026	PU
13/04	Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform	PR
16/03	Kazia Therapeutics : Half Yearly Report - 31 December 2025	PU
11/02	Kazia Therapeutics : Annual Report 2025	PU
30/01	Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)	PR
27/01	Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer	PR
08/01	Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End	PR
22/12	Kazia Therapeutics Regains Full Nasdaq Listing Compliance	PR
10/12	Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+	PR
02/12	Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities	PR
18/11	Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy	PR
27/10/25	Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner	PR
07/10/25	Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program	PR
02/10/25	Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen	PR
01/10/25	Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG	PR
11/09/25	Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy	PR